Recursion Pharmaceuticals (RXRX) Total Debt Growth (1y) (2021 - 2026)
Recursion Pharmaceuticals (RXRX) Total Debt Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 5.94% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | -34.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.30% |
| Dec 31, 2025 | -32.03% |
| Sep 30, 2025 | -27.53% |
| Jun 30, 2025 | -26.05% |
| Mar 31, 2025 | 2,237.35% |
| Dec 31, 2024 | 2,303.42% |
| Sep 30, 2024 | 2,451.42% |
| Jun 30, 2024 | 2,586.58% |
| Mar 31, 2024 | -9.16% |
| Dec 31, 2023 | 113.06% |
| Sep 30, 2023 | 100.71% |
| Jun 30, 2023 | 97.10% |
| Mar 31, 2023 | 93.28% |
| Dec 31, 2022 | -15.32% |
| Sep 30, 2022 | -14.48% |
| Jun 30, 2022 | -93.78% |
| Mar 31, 2022 | -94.10% |
| Dec 31, 2021 | -94.45% |